secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001438533-23-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere reports Q4 2022 net loss $65.8M; FDA granted accelerated approval for FILSPARI in IgAN
--------------------------------------------------------------------------------

- Net product sales $52.3M in Q4 2022 vs $54.6M in Q4 2021; full year $200.5M vs $210.8M.
- Net loss $65.8M ($1.03 per share) in Q4 2022 vs $51.6M ($0.84) in Q4 2021; full year loss $278.5M.
- Cash and marketable securities $450.2M as of Dec 31, 2022.
- FDA granted accelerated approval of FILSPARI (sparsentan) for IgAN on Feb 17, 2023; commercial launch expected week of Feb 27.
- Topline data from DUPLEX Study (FSGS) expected Q2 2023; EMA decision on sparsentan for IgAN expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/0001438533-23-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000006/tvtx-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer